About Weave
Weave Bio is an AI-native regulatory automation management platform redefining regulatory submissions for novel therapeutic candidates. Designed for pharma, biotechs, CROs, and consultants, the Weave Platform streamlines regulatory document preparation and lifecycle management by automating initial draft documents, extracting key insights, and integrating study data into a seamless, AI-enabled workflow.
The platform accelerates regulatory processes, enabling faster drafting, high-quality reviews, and compliance with global standards. AutoIND, widely adopted for preclinical IND submissions, earned the “Biotech AI Innovation of the Year” award. And with AutoCT, Weave expanded capabilities into clinical-stage submissions, building the foundation for a singular AI workbench for the entire therapy lifecycle.
Backed by top investors in AI and life sciences, Weave is creating a new AI-enabled, human-driven platform to enhance efficiency, submission quality, and cost-effectiveness.
Our Investors
We partner with industry-leading experts to bring the very best technology and insights to the company
How we got here


December 2023
Seed funding from Innovation Endeavors and Magnetic Ventures

January 2024
Company launch with a focus on platform development

March 2024
Early release of AutoIND, our AI-native solution for IND preparation

June 2024
Full commercial launch of AutoIND for pharma and biotech customers

November 2024
Weave Bio Earns the 2024 “BioTech AI Innovation Of The Year” Award
